Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Shooter 

Biogen Inc. diskutieren

Biogen Inc.

WKN: 789617 / Symbol: BIIB / Name: Biogen / Aktie / Pharmazeutika / Large Cap /

183,50 €
0,66 %

Biogen (BIIB) had its "buy" rating reaffirmed by Needham & Company LLC.
Ratings data for BIIB provided by MarketBeat

Biogen (BIIB) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
Ratings data for BIIB provided by MarketBeat

Einschätzung Buy
Rendite (%) -3,01 %
Kursziel 224,87
Veränderung
Endet am 29.06.27

Biogen (BIIB) had its price target raised by Needham & Company LLC from $255.00 to $256.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat

Biogen (BIIB) had its "reduce" rating reaffirmed by HSBC Holdings plc.
Ratings data for BIIB provided by MarketBeat

Biogen (BIIB) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Ratings data for BIIB provided by MarketBeat